Barclays lowered the firm’s price target on 10x Genomics to $45 from $47 and keeps an Overweight rating on the shares. The analyst says the company’s’ strong momentum in Xenium comes at the expense of Chromium.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TXG: